跳至主要内容
临床试验/EUCTR2017-002336-17-SE
EUCTR2017-002336-17-SE进行中(未招募)1 期

Randomized Evaluation of Decreased Usage of betablocCkErsafter myocardial infarction in the SWEDEHEART registryREDUCe SWEDEHEART - REDUCe SWEDEHEART

Department of Clinical Sciences, Danderyd Hospital, Karolinska Intitutet0 个研究点目标入组 5,020 人开始时间: 2017年6月15日最近更新:
适应症

试验速览

阶段
1 期
状态
进行中(未招募)
发起方
入组人数
5,020

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • 1.Age = 18 years.
  • 2.Day 1-7 after MI as defined by the universal definition of MI, type 1, included in the SWEDEHEART registry.
  • 3.Coronary angiography performed during hospitalization.
  • 4.Obstructive coronary artery disease documented by coronary angiography, i.e. stenosis = 50 %, FFR = 0.80 or iFR = 0.89 in any segment at any time point before randomization.
  • 5.Echocardiography performed after the MI showing a normal ejection fraction (EF=50%).
  • 6.Written informed consent obtained
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range 3500
  • F.1.3 Elderly (>=65 years) yes
  • F.1.3.1 Number of subjects for this age range 3500

排除标准

  • 1.Any condition that may influence the patient’s ability to comply with study protocol.
  • 2.Contraindications for beta-blockade
  • 3.Indication for beta-blockade other than as secondary prevention according to the treating physician
  • Thus, use of oral beta-blockade on admission is not per se an exclusion criterion.

研究者

发起方
Department of Clinical Sciences, Danderyd Hospital, Karolinska Intitutet

相似试验